Delivery Order SPE2DB22D2108-SPE2DB25FU5DP
- Not listed
- The Defense Logistics Agency awarded a $66,741.92 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $7,556.52 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with performance completion targeted for July 21, 2025. This delivery order represents a firm fixed-price, non-set-aside competitive award executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order valued at $3,804.40 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The contract is a firm fixed price delivery order issued on July 18, 2025, with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. No set-aside designation was used for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,545.48 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, awarded on July 18, 2025, with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a contract ceiling value of $1,703.81. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency (DLA) awarded a $12,891.92 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with an ultimate completion date of July 21, 2025. This competitive award, issued on July 18, 2025, utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $7,191.57 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price contract was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $15,380.88 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) for pharmaceutical supplies on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is valued at $30,825.02 and covers the delivery of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials to support federal medical procurement needs. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,782.72 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This firm fixed price delivery order, issued on July 18, 2025, with completion expected by July 21, 2025, was awarded without a set-aside designation through competitive procurement. The contract represents a fulfillment under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5DPDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $3,578.75. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's DLA IDC serves as a comprehensive global pharmaceutical support vehicle enabling the supply of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. This specific delivery order for Ozempic, a diabetes medication, reflects the company's capability to fulfill federal medical supply requirements through open competition and demonstrates its role in supporting the Defense Health Agency and other government healthcare systems through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/18/25 |